title: Hepatic ischemia/reperfusion injury can be modulated with thymoglobulin induction therapy.
abstract: BACKGROUND
  Thymoglobulin induction therapy has been shown to ameliorate delayed graft function and possibly decrease ischemia reperfusion injury in cadaver renal transplant recipients. This controlled randomized trial was designed to assess whether thymoglobulin also protects liver transplant recipients from ischemia reperfusion injury.
  
  
  METHODS
  Twenty-two cadaver liver transplant recipients were randomized to receive either thymoglobulin (1.5 mg/kg per dose) during the anhepatic period and two doses every other day or no thymoglobulin. No differences in recipient or donor demographics were present. Maintenance immunosupression consisted of tacrolimus (or cyclosporine) and steroids for both groups. Donor biopsies were obtained during organ procurement, cold storage, and 1 hour after revascularization. Postoperative liver function tests were monitored. Early graft function, length of stay, patient and graft survival rates, incidence of primary nonfunction, and rate of rejection were assessed.
  
  
  RESULTS
  Patient and graft survival at 3 months was 100%. There was no incidence of primary graft nonfunction and no need for retransplantation. The incidence of acute rejection was similar between the two groups. Although donor livers randomized to thymoglobulin had less optimal preimplantation biopsies, these recipients had significant decreases in ALT at day 1 compared to the control group (P = .02), near significant decreases of total bilirubin at day 5, and shorter length of hospitalization.
  
  
  CONCLUSIONS
  Thymoglobulin allowed for more compromised liver grafts to be transplanted with less clinical evidence of ischemia reperfusion injury and improved function.
authors.affiliation: Department of Surgery, Division of Transplantation, University of Illinois at Chicago, Chicago, Illinois 60612, USA.
authors.forename: D
authors.initials: D
authors.lastname: Bogetti
authors.forename: T M
authors.initials: TM
authors.lastname: Jarzembowski
authors.forename: H N
authors.initials: HN
authors.lastname: Sankary
authors.forename: A
authors.initials: A
authors.lastname: Manzelli
authors.forename: P S
authors.initials: PS
authors.lastname: Knight
authors.forename: G
authors.initials: G
authors.lastname: Chejfec
authors.forename: S
authors.initials: S
authors.lastname: Cotler
authors.forename: J
authors.initials: J
authors.lastname: Oberholzer
authors.forename: G
authors.initials: G
authors.lastname: Testa
authors.forename: E
authors.initials: E
authors.lastname: Benedetti
mesh_terms: D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D002102:Cadaver; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008099:Liver; D016031:Liver Transplantation / Q000276:immunology*; D015427:Reperfusion Injury / Q000517:prevention & control*; D014019:Tissue Donors
chemical_list: D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents